Syros Pharmaceuticals, Inc. - common stock (SYRS) News
Filter SYRS News Items
SYRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SYRS News Highlights
- For SYRS, its 30 day story count is now at 4.
- Over the past 13 days, the trend for SYRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- PRE are the most mentioned tickers in articles about SYRS.
Latest SYRS News From Around the Web
Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsCAMBRIDGE, Mass., December 19, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,242,588 shares of its common stock at an offering price of $4.419 p |
individual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last weekKey Insights Syros Pharmaceuticals' significant individual investors ownership suggests that the key decisions are... |
Syros (SYRS) Rises on Upbeat Initial Study Data on TamibaroteneSyros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia. |
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineCAMBRIDGE, Mass., December 06, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia |
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside PotentialIf the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. |
Syros to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., November 21, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Management will also be available for one-on-one meetings. Details are as follows: |
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call TranscriptSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Syros Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of Syros’ website at www.syros.com. Please be advised that today’s call is being recorded. […] |
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateCAMBRIDGE, Mass., November 14, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update. |
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue EstimatesKALA BIO (KALA) delivered earnings and revenue surprises of -58.60% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023CAMBRIDGE, Mass., November 07, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 14, 2023 to report its third quarter 2023 financial results and provide a corporate update. |